Economic Burden of Psoriasis: A Review of Literature

Nor Azmaniza Azizam, Aniza Ismail, Saperi Sulong, Norazirah Md Nor and Zafar Ahmed
Additional contact information
Nor Azmaniza Azizam: Universiti Teknologi MARA, Selangor, Malaysia
Aniza Ismail: Universiti Kebangsaan Malaysia, Malaysia
Saperi Sulong: Universiti Kebangsaan Malaysia, Malaysia
Norazirah Md Nor: Universiti Kebangsaan Malaysia, Malaysia
Zafar Ahmed: Universiti Kebangsaan Malaysia, Malaysia

International Journal of Business and Administrative Studies, 2015, vol. 1, issue 1, 18-22

Abstract: Psoriasis is a chronic inflammatory skin disease that primarily affects the skin and joints. Although the disease is known to be non-life threatening, psoriasis patients usually need lifelong care, which equals lifetime expenses. Many cost analysis studies on psoriasis have not been comprehensive in calculating both its direct and indirect costs, and there are very limited studies on the economic burden of this disease in Asian countries. Therefore, a systematic literature review was done to gain a comprehensive understanding of the economic burden of psoriasis throughout the world. Observational studies and randomized controlled trials (RCTs) published in the period 2000 to 2014 and reporting on the direct and indirect costs of psoriasis was included. The search for literatures in the PUBMED database using keyword "economic burden of psoriasis", "direct cost" and indirect cost" has produced 182 articles. Of all the articles identified, 37 reports studies have met the inclusion criteria. Direct costs were found to be higher than indirect costs, with hospitalization, medication prescription, travel, and treatment costs as significant aspects. Loss of productivity and wage (indirect costs borne by the patient) is not uncommon among psoriasis patients, accounting for 30-50% of the total cost, with an average of 2.2 work hours lost due to psoriasis. The limited information on such cost analysis justifies the need for future studies that address the cost of psoriasis therapies so as to provide the necessary transparency to guarantee reasonable medical care that takes into account the cost-benefit ratio and the best outcome for the patient’s quality of life.

Keywords: Psoriasis; Direct Cost; Indirect Cost; Economic Burden (search for similar items in EconPapers)
Date: 2015
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://kkgpublications.com/business-administrative-studies-article-3/ (application/pdf)
https://kkgpublications.com/wp-content/uploads/2015/12/IJBAS10003.pdf (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:apa:ijbaas:2015:p:18-22

DOI: 10.20469/ijbas.1.10003-1

Access Statistics for this article

International Journal of Business and Administrative Studies is currently edited by Professor Dr. Bahaudin G. Mujtaba

More articles in International Journal of Business and Administrative Studies from Professor Dr. Bahaudin G. Mujtaba Calle Alarcon 66, Sant Adrian De Besos 08930, Barcelona Spain.
Bibliographic data for series maintained by Professor Dr. Bahaudin G. Mujtaba ().